EP1589996A4 - Preparation d'anticorps anti-integrine alpha beta 3 et utilisations associees - Google Patents

Preparation d'anticorps anti-integrine alpha beta 3 et utilisations associees

Info

Publication number: EP1589996A4
Authority: EP; European Patent Office
Prior art keywords: antibody; integrin alpha; alpha beta; formulat ions; formulat
Prior art date: 2003-01-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP04707034A

Other languages

German (de)

English (en)

Other versions

EP1589996A2 (fr

Inventor

Christian B Allan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

MedImmune LLC

Original Assignee

MedImmune LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-30

Filing date

2004-01-30

Publication date

2009-01-21

2004-01-30 Application filed by MedImmune LLC filed Critical MedImmune LLC

2005-11-02 Publication of EP1589996A2 publication Critical patent/EP1589996A2/fr

2009-01-21 Publication of EP1589996A4 publication Critical patent/EP1589996A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Heart & Thoracic Surgery (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

EP04707034A 2003-01-30 2004-01-30 Preparation d'anticorps anti-integrine alpha beta 3 et utilisations associees Withdrawn EP1589996A4 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US44381003P	2003-01-30	2003-01-30
US44377703P	2003-01-30	2003-01-30
US443777P		2003-01-30
US443810P		2003-01-30
PCT/US2004/002701 WO2004066957A2 (fr)	2003-01-30	2004-01-30	Preparation d'anticorps anti-integrine $g(a)v$g(b)3 et utilisations associees

Publications (2)

Publication Number	Publication Date
EP1589996A2 EP1589996A2 (fr)	2005-11-02
EP1589996A4 true EP1589996A4 (fr)	2009-01-21

Family

ID=32829839

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP04707034A Withdrawn EP1589996A4 (fr)	2003-01-30	2004-01-30	Preparation d'anticorps anti-integrine alpha beta 3 et utilisations associees

Country Status (5)

Country	Link
EP (1)	EP1589996A4 (fr)
JP (1)	JP2006516636A (fr)
AU (1)	AU2004207003A1 (fr)
CA (1)	CA2512174A1 (fr)
WO (1)	WO2004066957A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7973134B2 (en)	2004-07-07	2011-07-05	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
US20060046961A1 (en) *	2004-09-02	2006-03-02	Mckay William F	Controlled and directed local delivery of anti-inflammatory compositions
US7935790B2 (en)	2004-10-04	2011-05-03	Cell Singaling Technology, Inc.	Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
US7807789B2 (en)	2004-12-21	2010-10-05	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
JP2009503105A (ja)	2005-08-03	2009-01-29	イミュノジェン・インコーポレーテッド	免疫複合体製剤
EP1934867A2 (fr)	2005-08-31	2008-06-25	Cell Signaling Technology, Inc.	Reactifs de detection de phosphorylation proteinique dans des voies de signalisation de leucemie
KR20080110800A (ko)	2006-03-15	2008-12-19	알렉시온 파마슈티칼스, 인코포레이티드	보체의 저해물질로 발작성 야간혈색뇨증 환자의 치료
US7939636B2 (en)	2006-08-11	2011-05-10	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in c-Src signaling pathways
JP5695317B2 (ja)	2006-09-05	2015-04-01	アレクシオンファーマシューティカルズ，インコーポレイテッド	抗体媒介性ニューロパシーを処置するための方法および組成物
AU2007309616B2 (en)	2006-10-20	2011-10-06	Amgen Inc.	Stable polypeptide formulations
EP1972639A3 (fr)	2007-03-07	2008-12-03	Cell Signaling Technology, Inc.	Réactifs pour la détection de la phosphorylation de protéines dans des voies signalant un carcinome
US20090068684A1 (en)	2007-03-26	2009-03-12	Cell Signaling Technology, Inc.	Serine and threoninephosphorylation sites
WO2008121301A1 (fr)	2007-03-29	2008-10-09	Abbott Laboratories	Anticorps anti-il-12 humains cristallins
EP2145902A3 (fr)	2007-04-19	2010-09-29	Peter Hornbeck	Sites de phosphorylation à tyrosine et anticorps spécifiques
US7977462B2 (en)	2007-04-19	2011-07-12	Cell Signaling Technology, Inc.	Tyrosine phosphorylation sites
EP1983003A3 (fr)	2007-04-19	2009-03-11	Peter Hornbeck	Sites de phosphorylation à tyrosine et anticorps spécifiques
US20090053831A1 (en)	2007-05-01	2009-02-26	Cell Signaling Technology, Inc.	Tyrosine phosphorylation sites
MX2010003743A (es) *	2007-10-09	2010-05-03	Hercules Inc	Composiciones adhesivas que contienen entrelazador.
US20090203043A1 (en)	2007-11-21	2009-08-13	Peter Hornbeck	Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
US8883146B2 (en)	2007-11-30	2014-11-11	Abbvie Inc.	Protein formulations and methods of making same
JP5808349B2 (ja)	2010-03-01	2015-11-10	カリスライフサイエンシズスウィッツァーランドホールディングスゲーエムベーハー	セラノーシスのためのバイオマーカー
CA2794631A1 (fr) *	2010-03-31	2011-10-06	Universite De Geneve	Preparations d'anticorps stabilises et utilisations correspondantes
EP2556172A4 (fr)	2010-04-06	2013-10-30	Caris Life Sciences Luxembourg Holdings	Biomarqueurs circulants pour une maladie
US10316095B2 (en) *	2012-02-16	2019-06-11	Santarus, Inc.	Antibody formulations
SG11201703152RA (en)	2014-10-23	2017-05-30	Amgen Inc	Reducing viscosity of pharmaceutical formulations
AU2017274442B2 (en)	2016-06-02	2021-08-19	Abbvie Inc.	Glucocorticoid receptor agonist and immunoconjugates thereof
JP7377596B2 (ja)	2017-02-22	2023-11-10	アムジエン・インコーポレーテツド	低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
WO2019106609A1 (fr)	2017-12-01	2019-06-06	Abbvie Inc.	Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci
WO2020060183A1 (fr) *	2018-09-18	2020-03-26	삼성바이오에피스 주식회사	Formation de liquide pour stabiliser un anticorps de trastuzumab
EP3907504A4 (fr) *	2019-01-04	2022-11-30	Kyoto University	Méthode de test pour la rectocolite hémorragique et la cholangite sclérosante primitive

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010016645A1 (en) *	1997-01-30	2001-08-23	Ixsys, Incorporated	Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use
WO2002013860A1 (fr) *	2000-08-11	2002-02-21	Chugai Seiyaku Kabushiki Kaisha	Preparations stabilisees contenant un anticorps

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6267958B1 (en) *	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation

2004
- 2004-01-30 AU AU2004207003A patent/AU2004207003A1/en not_active Abandoned
- 2004-01-30 JP JP2006503199A patent/JP2006516636A/ja not_active Withdrawn
- 2004-01-30 CA CA002512174A patent/CA2512174A1/fr not_active Abandoned
- 2004-01-30 WO PCT/US2004/002701 patent/WO2004066957A2/fr active Application Filing
- 2004-01-30 EP EP04707034A patent/EP1589996A4/fr not_active Withdrawn

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010016645A1 (en) *	1997-01-30	2001-08-23	Ixsys, Incorporated	Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use
WO2002013860A1 (fr) *	2000-08-11	2002-02-21	Chugai Seiyaku Kabushiki Kaisha	Preparations stabilisees contenant un anticorps
EP1314437A1 (fr) *	2000-08-11	2003-05-28	Chugai Seiyaku Kabushiki Kaisha	Preparations stabilisees contenant un anticorps

Also Published As

Publication number	Publication date
EP1589996A2 (fr)	2005-11-02
AU2004207003A1 (en)	2004-08-12
CA2512174A1 (fr)	2004-08-12
WO2004066957A2 (fr)	2004-08-12
JP2006516636A (ja)	2006-07-06
WO2004066957A3 (fr)	2005-04-07

Publication	Publication Date	Title
EP1589996A4 (fr)	2009-01-21	Preparation d'anticorps anti-integrine alpha beta 3 et utilisations associees
IL225633B (en)	2021-12-01	Anti-alpha-v-beta - 6 antibodies and uses thereof
IL174637A0 (en)	2006-08-20	Fibrosis-inducing agents, compositions containing the same and medical implants containing the same
AU2003272187A8 (en)	2004-01-06	Novel nanoparticles and use thereof
IL173299A (en)	2015-05-31	2,4-Pyrimidindiamine derivatives, preparations containing them and their use
EP1539941A4 (fr)	2006-11-29	Adzymes et leurs utilisations
AU2003295402A8 (en)	2004-06-03	Acyl guanidine compounds and use thereof
PT1736541E (pt)	2013-01-31	Nova proteína galectina 9 modificada e sua utilização
GB0220214D0 (en)	2002-10-09	Compounds and their use
AU2003296369A8 (en)	2004-06-30	Imminoamines and preparation thereof
AU2003215257A8 (en)	2003-09-09	Modified defensins and their use
EP1767634A4 (fr)	2008-10-22	Nouvelle proteine de modification galectine 8 et utilisation de celle-ci
AU2003231827A8 (en)	2003-12-12	Pseudo-tissues and uses thereof
AU2003275123A8 (en)	2004-04-08	Composition containing ribavirin and use thereof
GB0227906D0 (en)	2003-01-08	Compounds and their use
HK1134030A1 (en)	2010-04-16	Survivin-derived peptides and use thereof
GB0218031D0 (en)	2002-09-11	Compounds and their use
FR2859108B1 (fr)	2008-01-11	Composition anti-stress et son inhalateur
AU2003216442A8 (en)	2003-09-09	Enkurin and uses thereof
GB2420345B (en)	2008-07-23	3-alpha-glycosyl alpha, alpha-trehaloses their preparation and use
GB0321300D0 (en)	2003-10-15	Protein structure and uses thereof
GB0220215D0 (en)	2002-10-09	Compounds and their use
GB0228538D0 (en)	2003-01-15	Protein structure and uses thereof
GB0311163D0 (en)	2003-06-18	Composition and use
GB0325237D0 (en)	2003-12-03	Composition and use

Legal Events

Date	Code	Title	Description
2005-09-16	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2005-11-02	17P	Request for examination filed	Effective date: 20050816
2005-11-02	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
2005-11-02	AX	Request for extension of the european patent	Extension state: AL LT LV MK
2006-05-17	DAX	Request for extension of the european patent (deleted)
2009-01-21	A4	Supplementary search report drawn up and despatched	Effective date: 20081219
2009-10-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2009-11-11	18D	Application deemed to be withdrawn	Effective date: 20090318